Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants

Diabetes Care

Volumn 33, Issue 3, 2010, Pages 620-625

  Sosenko, Jay M ^a   Palmer, Jerry P ^b   Rafkin, Lisa E ^a   Krischer, Jeffrey P ^c   Cuthbertson, David ^c   Greenbaum, Carla J ^d   Eisenbarth, George ^e   Skyler, Jay S ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE;

ARTICLE; CHILD; DIABETIC PATIENT; DISEASE COURSE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PREVENTION STUDY; SCHOOL CHILD;

ADOLESCENT; AREA UNDER CURVE; C-PEPTIDE; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; LONGITUDINAL STUDIES; MALE; PREDIABETIC STATE; TIME FACTORS;

EID: 77649244995     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1770     Document Type: Article

References (12)

1. Sherry NA, Tsai EB, Herold KC. Natural history of β-cell function in type 1 diabetes. Diabetes 2005;54 (Suppl. 2):S32-S39
2. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-649
3. Skyler JS. Prediction and prevention of type 1 diabetes. Clin Pharm Ther 2007; 81:768-771
4. Eisenbarth GS. Update in type 1 diabetes. J Clin Endocrinol Metab 2007;92:2403-2407
5. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, Diabetes Prevention Trial-Type 1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes. Diabetes Care 2007;30: 38-42
6. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler JS. Glucose and C-peptide changes in the peri-onset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
7. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
8. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care 2005;28:1068-1076
9. Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP. Diabetes Prevention Trial 1: Prevalence of GAD and ICA512 (IA-2) autoantibodies by relationship to proband. Ann N Y Acad Sci 2002;958:254-258
10. Nagi DK, Knowler WC, Charles MA, Liu QZ, Hanson RL, McCance DR, Pettitt DJ, Bennett PH. Early and late insulin response as predictors of NIDDM in Pima Indians with impaired glucose tolerance. Diabetologia 1995;38:187-192
11. Yalow RS, Glick SM, Roth J, Berson SA. Plasma insulin and growth hormone levels in obesity and diabetes. Ann N Y Acad Sci 1965;131:357-373
12. Bagdade JD, Bierman EL, Porte D Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967;41:1549-1557